Pitavastatin lives trial
WebIn a double-blind, randomized, controlled, 52-week trial, 252 HIV-infected patients with dyslipidemia were treated with either LIVALO 4 mg once daily (n=126) or another statin … WebResults: The mean daily dose of rosuvastatin and pitavastatin was 2.5 mg and 1.4 mg, respectively. All lipid parameters were significantly more improved in the rosuvastatin …
Pitavastatin lives trial
Did you know?
WebJan 18, 2024 · Pitavastatin significantly and continuously increased HDL-C over 2 years. Interestingly, the percentage increase in HDL-C was higher in patients with baseline … WebJun 30, 2024 · Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Web2 days ago · April 12, 2024. An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong evidence of efficacy and ... WebThe Livalo Effectiveness and Safety (LIVES) study was an observational study to examine the efficacy and safety of pitavastatin, a newly developed drug, in approximately 20,000 Japanese patients with hypercholesterolemia. During a 2-year follow-up period, no significant problems concerning safety were observed upon treatment with pitavastatin.
WebNov 1, 2011 · Compared to other statins, pitavastatin is a highly potent 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor and an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Its characteristic structure (heptenoate as the basic structure, a core quinoline ring and side chains that include fluorophenyl and ... WebFeb 6, 2024 · LIVALO demonstrated: Potent LDL-C reduction up to a mean of 45% at the 4-mg dose*1-4. According to the 2024 ACC/AHA Guideline on the Management of Blood Cholesterol, moderate-intensity statins provide average LDL-C reductions of 30% to <50% 5. Comparable efficacy at the 2-mg and 4-mg doses to commonly prescribed strengths of …
WebFeb 6, 2024 · LIVALO demonstrated: Potent LDL-C reduction up to a mean of 45% at the 4-mg dose*1-4. According to the 2024 ACC/AHA Guideline on the Management of Blood …
WebJun 22, 2024 · Results: Of the 18,846 participants, 5,898 (31.3%) were taking statins at baseline. At baseline, statin users were more likely than nonusers to be women, to have <12 years’ education, and to have obesity, chronic kidney disease, diabetes, and hypertension. During follow-up, 566 incident cases of dementia and 380 incident cases of MCI were ... hotels nevers franceWebImportance of the field: Many clinical trials of pitavastatin have been done since its launch. New insights on pitavastatin from these trials are summarized and evaluated. Areas covered in this review: The results of clinical studies using pitavastatin, from 2008 to 2009, the LIVES study, the JAPAN-ACS study, the CHIBA study, the PIAT study and Phase III … hotels newark airport america\u0027s bestWebJan 22, 2015 · Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery … lims selectionWebMay 23, 2024 · Previous randomized clinical trial demonstrated that pitavastatin 4 mg compared with pitavastatin 1 mg therapy significantly reduced LDL-C and clinical outcomes irrespective of renal function ... Shimano H, Urashima M, Teramoto T Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and … lims service setaWebA 2009 study of the 104-week LIVES trial found pitavastatin increased HDL cholesterol, especially in patients with HDL lower than 40 mg/dL, who had a 24.6% rise, ... lims searchWeb2 days ago · April 12, 2024. An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong … lims servicesWebAim: To determine the lipid lowering effectiveness, cost effectiveness, and safety of rosuvastatin compared with pitavastatin in dyslipidemic patients with concurrent renal disorders. Methods: This single-center, prospective, open-label, randomized, 12-month study evaluated rosuvastatin (2.5 mg) and pitavastatin (1 or 2 mg) in 134 dyslipidemic … lims service has stopped